alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
NOTICE TO CLERK OF COURT: Please accept this Initiating Complaint as an initial pleading 

pursuant to CMO __, dated ____________, of Hon. Alvin K. Hellerstein in In Re World Trade 

Center Lower Manhattan Disaster Site Litigation, 21 MC 102 (AKH). 

UNITED STATES DISTRICT COURT 

SOUTHERN DISTRICT OF NEW YORK 

--------------------------------------------------------------X 

 

IN RE WORLD TRADE CENTER LOWER 

MANHATTAN DISASTER SITE LITIGATION 

 

--------------------------------------------------------------X 

21 MC 102 (AKH) 

--------------------------------------------------------------X 

XXXXX, 

 Plaintiff(s), 

 -againstXXXXX, 

 Defendants. 

--------------------------------------------------------------X 

 XX Civ. XXXX (AKH) 

INITIATING COMPLAINT

Pursuant to Case Management Order No. __ (“CMO __”) dated June __, 2007 by Hon. 

Alvin K. Hellerstein, U.S.D.J., in In Re World Trade Center Lower Manhattan Disaster Site 

Litigation, 21 MC 102 (AKH), Plaintiff(s) hereby submit this Initiating Complaint against the 

above named Defendants and state: 

1. Plaintiff ____________ (XXXX) [Å last 4 digits of social security number] 

currently resides at ______________. 

2. Plaintiff(s) have a claim for injury against the Defendants named above that 

would be encompassed within the scope of the In Re World Trade Center Lower Manhattan 

Disaster Site Litigation, 21 MC 102 (AKH). 

3. Plaintiffs will file a fully complete Check-Off Complaint under this docket 

number within 30 days of the filing of this Initiating Complaint. 

Case 1:07-cv-05303-AKH Document 2-4 Filed 06/29/2007 Page 1 of 2
NOTICE TO CLERK OF COURT: Please accept this Initiating Complaint as an initial pleading 

pursuant to CMO __, dated ____________, of Hon. Alvin K. Hellerstein in In Re World Trade 

Center Lower Manhattan Disaster Site Litigation, 21 MC 102 (AKH). 

Dated: _____ __, 200X 

{law firm name} 

Attorney(s) for 

Plaintiff(s)_______________________ 

By: ________ 

 {name} 

{law firm address} 

Telephone: _______________ 

Case 1:07-cv-05303-AKH Document 2-4 Filed 06/29/2007 Page 2 of 2
# C_2009278EN.01001701.xml

| 18.11.2009 | EN | Official Journal of the European Union | C 278/17 |
| --- | --- | --- | --- |

18.11.2009

EN

Official Journal of the European Union

C 278/17

---

Commission communication pursuant to Article 16(4) of Regulation (EC) No 1008/2008 of the European Parliament and of the Council on common rules for the operation of air services in the Community

Public service obligations (modified) in respect of scheduled air services

2009/C 278/08

| Member State | United Kingdom |
| --- | --- |
| Concerned routes | Oban–Coll
  Oban–Colonsay
  Oban–Tiree
  Coll–Tiree |
| Date of entry into force of the public service obligations | 2 March 2007 |
| Address where the text and any relevant information and/or documentation related to the modified public service obligations can be obtained | Argyll and Bute Council |
| Council Offices |
| Kilmory |
| Lochgilphead |
| Argyll |
| PA31 8RT |
| Scotland |
| UNITED KINGDOM |
| Tel. +44 1546604611 |
| Fax +44 1546606443 |
| (Contact: Stewart Turner, Operational Services) |
| E-mail: stewart.turner@argyll-bute.gsx.gov.uk |

Member State

United Kingdom

Concerned routes

Oban–Coll

Oban–Colonsay

Oban–Tiree

Coll–Tiree

Date of entry into force of the public service obligations

2 March 2007

Address where the text and any relevant information and/or documentation related to the modified public service obligations can be obtained

Argyll and Bute Council

Council Offices

Kilmory

Lochgilphead

Argyll

PA31 8RT

Scotland

UNITED KINGDOM

Tel. +44 1546604611

Fax +44 1546606443

(Contact: Stewart Turner, Operational Services)

E-mail: stewart.turner@argyll-bute.gsx.gov.uk

---
<TABLE> <S> <C>

<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION AS OF AND FOR THE NINE
MONTHS ENDED SEPT. 30, 1999, EXTRACTED FROM BALANCE SHEETS AND STATEMENTS OF
OPERATIONS AND IS QUALIFIED IN ITS ENTIRETY BY REFERENCE TO SUCH FINANCIAL
STATEMENTS CONTAINED IN THIS FORM 10Q.
</LEGEND>
<CIK> 0001045710
<NAME> FRONTIERVISION HOLDINGS, LP
<MULTIPLIER> 1,000

<S>                             <C>
<PERIOD-TYPE>                   9-MOS
<FISCAL-YEAR-END>                          DEC-31-1999
<PERIOD-END>                               SEP-30-1999
<CASH>                                              95
<SECURITIES>                                         0
<RECEIVABLES>                                   11,068
<ALLOWANCES>                                         0
<INVENTORY>                                          0
<CURRENT-ASSETS>                                     0
<PP&E>                                         370,666
<DEPRECIATION>                               1,187,399
<TOTAL-ASSETS>                                       0
<CURRENT-LIABILITIES>                                0
<BONDS>                                      1,136,420
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                             0
<OTHER-SE>                                     (58,540)
<TOTAL-LIABILITY-AND-EQUITY>                 1,187,399
<SALES>                                              0
<TOTAL-REVENUES>                               221,032
<CGS>                                                0
<TOTAL-COSTS>                                  253,815
<OTHER-EXPENSES>                                (8,961)
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                              77,962
<INCOME-PRETAX>                               (101,784)
<INCOME-TAX>                                    (2,082)
<INCOME-CONTINUING>                            (99,702)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                         0
<EPS-BASIC>                                          0
<EPS-DILUTED>                                        0


</TABLE>
“r 

. . . . 

C 

-..:.o 

OFFICE OF THE ATTORNEY GENERAL OF TW 

AU-IN 
-. ..’ 

. ’ 

‘Y’ e-4 

Honordl* Bomor Qorrlm4, Jr., ~860 8 

, 

.: ,-tbkrtioo. d, er tb0 r0ryoiy utloi0 a 300~ 

tion ok800 Wko8 uy ragululy oonotitu8od puao 

arrieu ritbmg a 

4r 

in ~oooaoolon 0r a u$er 

rohlole IoCor, so blook, or l ry pera OhorNY, 

en rhioi Me no8u mubar, mor&oSnl mmbor, or ma&afu8ur.r. muher, ho. born l l$omd ohugod 

or la M la u1 1l he, ll inre4lmtr4 t&. iuoa do *mod, 

~00oooo il wh o n mo8u whlol*, end ehall 8*U. Uao 

l r Y r er 0 o ur r i.bino o$ g $b o f tiiuë8o , 0 #tP sulob 

M utlt~ and aok. oha wooar# inTo8t~tL# h 

daumiuo owluoh~.‘”
<PAGE>

                                                                      EXHIBIT 11

                           APEX MORTGAGE CAPITAL, INC.
                        COMPUTATION OF EARNINGS PER SHARE

<TABLE>
<CAPTION>
                                                               QUARTER ENDED
                                                     MARCH 31, 1999       MARCH 31, 1998
                                                  ----------------------------------------
<S>                                               <C>                    <C>
BASIC:

Net Income                                                 2,962,000              564,000

Average Number of Shares Oustanding                        5,753,000            6,603,000

Basic Earnings Per Share                                        0.51                 0.09


DILUTED:

Effect of dilutive securities:
Incremental shares from dilutive stock options                20,000                    -

Diluted Average Number of Shares Outstanding               5,773,000            6,603,000

                                                  ----------------------------------------
Diluted Earnings Per Share                                     $0.51                $0.09
                                                  ----------------------------------------
                                                  ----------------------------------------
</TABLE>
Case 1:07-cv-05312-AKH Document 5 Filed 08/07/2007 Page 1 of 4Case 1:07-cv-05312-AKH Document 5 Filed 08/07/2007 Page 2 of 4Case 1:07-cv-05312-AKH Document 5 Filed 08/07/2007 Page 3 of 4Case 1:07-cv-05312-AKH Document 5 Filed 08/07/2007 Page 4 of 4
[Federal Register Volume 66, Number 90 (Wednesday, May 9, 2001)]
[Notices]
[Pages 23721-23722]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 01-11598]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Center for Scientific Review; Notice of Closed Meetings

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended (5 U.S.C. Appendix 2), notice is hereby given of the following 
meetings.
    The meetings will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: Center for Scientific Review Special Emphasis 
Panel.
    Date: May 2, 2001.
    Time: 10 a.m. to 11 a.m.
    Agenda: To review and evaluate grant applications.
    Place: NIH, Rockledge 2, Bethesda, MD 20892, (Telephone 
Conference Call).
    Contact Person: Russell T. Dowell, PhD, Scientific Review 
Administrator, Center for Scientific Review, National Institutes of 
Health, 6701 Rockledge Drive, Room 4118, MSC 7818, Bethesda, MD 
20892, (301) 435-1169, <a href="/cdn-cgi/l/email-protection#b4d0dbc3d1d8d8c6f4d0c6d39adadddc9ad3dbc2"><span class="__cf_email__" data-cfemail="e5818a9280898997a5819782cb8b8c8dcb828a93">[email protected]</span></a>.
    This notice is being published less than 15 days prior to the 
meeting due to the timing limitations imposed by the review and 
funding cycle.


[[Page 23722]]


    Name of Committee: Center for Scientific Review Special Emphasis 
Panel.
    Date: May 4, 2001.
    Time: 2 p.m. to 3 p.m.
    Agenda: To review and evaluate grant applications.
    Place: NIH, Rockledge 2, Bethesda, MD 20892, (Telephone 
Conference Call).
    Contact Person: Michael A. Lang, PhD, Scientific Review 
Administrator, Center for Scientific Review, National Institutes of 
Health, 6701 Rockledge Drive, Room 5210, MSC 7850, Bethesda, MD 
20892, (301) 435-1265.
    This notice is being published less than 15 days prior to the 
meeting due to the timing limitations imposed by the review and 
funding cycle.

(Catalogue of Federal Domestic Assistance Program Nos. 93.306, 
Comparative Medicine, 93.306; 93.333, Clinical Research, 93.333, 
93.337, 93.393-93.396, 93.837-93.844, 93.846-93.878, 93.892, 93.893, 
National Institutes of Health, HHS)

    Dated: May 1, 2001.
LaVerne Y. Stringfield,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. 01-11598 Filed 5-8-01; 8:45 am]
BILLING CODE 4140-01-M


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>
Clear All

        05 September 2023    

                    USS Arleigh Burke (DDG 51) Holds Change of Command Ceremony                 
                The Arleigh Burke-class guided-missile destroyer USS Arleigh Burke (DDG 51) held its change of command ceremony at Pier 1 in Naval Station Rota, Spain, August 24, 2023.            

        11 June 2023    

                    USS Arleigh Burke (DDG 51) arrives in Agadir, Morocco                 
                The Arleigh Burke-class guided-missile destroyer USS Arleigh Burke (DDG 51) arrived in Agadir, Morocco for a scheduled port visit, June 10, 2023.            

        16 May 2023    

                    USS Arleigh Burke (DDG 51) arrives in Limassol, Cyprus                 
                The Arleigh Burke-class guided-missile destroyer USS Arleigh Burke (DDG 51) arrived in Limassol, Cyprus for a scheduled port visit, May 16, 2023.            

        15 June 2022    

                    USS Arleigh Burke begins second Forward Deployed Naval Forces-Europe patrol                 
                Forward-deployed Naval Forces-Europe (FDNF-E) Arleigh Burke-class guided-missile destroyer USS Arleigh Burke (DDG 51) departed Naval Station Rota, Spain to begin its second (FDNF-E) patrol, June 1, 2022.            

#####  

##### Navy.mil  |  Navy.com  |  Navy FOIA  |  DoD Accessibility/Section 508  |  No Fear Act  |  Open Government  |  Plain Writing Act USA.gov  |  Veterans Crisis Line  |  VA Vet Center  |  FVAP  |   DoD Safe Helpline  |  Navy SAPR  |  NCIS Tips  |  Privacy Policy  |  Site Map  |  Contact US

###### Commander, U.S. Fleet Forces Command   |   1562 Mitscher Ave., Suite 250   |   Norfolk, Virginia 23551-2487

###### Official U.S. Navy Website
[Exhibit 32.2]

   CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO 18 U.S.C.
       SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE
                     SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-QSB/A of Med Gen,
Inc. (the "Company") for the quarter ended June 30, 2006 as filed with
the Securities and Exchange Commission on the date hereof (the
"Report"), the undersigned, Jack Chien, Chief Financial Officer of the
Company, hereby certifies, pursuant to 18 U.S.C.
Section 1350, that:

(1) the Report fully complies with the requirements of Section 13(a)
or 15(d) of the Securities Exchange Act of 1934, as amended; and

(2) the information contained in the Report fairly presents, in all
material respects, the financial condition and results of operations
of the Company.


Date: August 14, 2006

                                    	   /s/ JACK CHIEN
                                              -----------------------
                                              Jack Chien
                                              Chief Financial Officer
<TABLE> <S> <C>


<ARTICLE>                     5
<LEGEND>
This Schedule contains summary financial information extracted from Baron
Capital Trust's financial statements for the three months ended June 30, 2000
and is qualified in its entirety by reference to such financial statements.
</LEGEND>

<S>                             <C>
<PERIOD-TYPE>                   3-MOS
<FISCAL-YEAR-END>                              DEC-31-2000
<PERIOD-END>                                   JUN-30-2000
<CASH>                                             890,341
<SECURITIES>                                             0
<RECEIVABLES>                                    7,704,267
<ALLOWANCES>                                             0
<INVENTORY>                                              0
<CURRENT-ASSETS>                                 9,685,655
<PP&E>                                          39,568,434
<DEPRECIATION>                                  (6,414,750)
<TOTAL-ASSETS>                                  47,116,585
<CURRENT-LIABILITIES>                            2,574,290
<BONDS>                                         28,981,886
<PREFERRED-MANDATORY>                                    0
<PREFERRED>                                              0
<COMMON>                                        29,780,835
<OTHER-SE>                                     (14,414,819)
<TOTAL-LIABILITY-AND-EQUITY>                    47,116,585
<SALES>                                                  0
<TOTAL-REVENUES>                                 2,033,899
<CGS>                                                    0
<TOTAL-COSTS>                                    2,242,519
<OTHER-EXPENSES>                                 1,105,573
<LOSS-PROVISION>                                         0
<INTEREST-EXPENSE>                                 660,580
<INCOME-PRETAX>                                 (9,670,832)
<INCOME-TAX>                                             0
<INCOME-CONTINUING>                                      0
<DISCONTINUED>                                           0
<EXTRAORDINARY>                                          0
<CHANGES>                                                0
<NET-INCOME>                                    (9,670,832)
<EPS-BASIC>                                         (14.01)
<EPS-DILUTED>                                       (14.01)



</TABLE>
Case 1:07-cv-01546-AKH Document 3 Filed 08/03/2007 Page 1 of 5
Case 1:07-cv-01546-AKH Document 3 Filed 08/03/2007 Page 2 of 5
Case 1:07-cv-01546-AKH Document 3 Filed 08/03/2007 Page 3 of 5
Case 1:07-cv-01546-AKH Document 3 Filed 08/03/2007 Page 4 of 5
Case 1:07-cv-01546-AKH Document 3 Filed 08/03/2007 Page 5 of 5
[Federal Register Volume 66, Number 10 (Tuesday, January 16, 2001)]
[Notices]
[Pages 3618-3619]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 01-1125]


=======================================================================
-----------------------------------------------------------------------

NATIONAL AERONAUTICS AND SPACE ADINISTRATION

[Notice 01-004]


Notice of Prospective Patent License

AGENCY: National Aeronautics and Space Administration.

ACTION: Notice of prospective patent license.

-----------------------------------------------------------------------

SUMMARY: NASA hereby gives notice that CJAB Associates, LLP, of 
Houston, TX, has applied for a partially exclusive license to practice 
the inventions described and claimed in U.S. Patent No. 5,153,132, 
entitled ``Three-Dimensional Co-Culture Process;'' U.S. Patent No. 
5,153,133, entitled ``Method for Culturing Mammalian Cells in a 
Horizontally Rotated Bioreactor;'' U.S. Patent No. 5,155,034, entitled 
``Three-Dimensional Cell to Tissue Assembly Process;'' U.S. Patent No. 
5,155,035, entitled ``Method for Culturing Mammalian Cells in a 
Perfused Bioreactor;'' U.S. Patent No. 5,308,764, entitled ``Multi-
Cellular Three Dimensional Living Mammalian Tissue;'' U.S. Patent No. 
5,496,722, entitled ``Method for Producing Non-Neoplastic, 3-
Dimensional Mammalian Tissue and Cell Aggregates under

[[Page 3619]]

Microgravity Culture Conditions and the Products Produced Thereby;'' 
U.S. Patent No. 5,627,021, entitled``Multi-Cellular, Three-Dimensional 
Living Mammalian Tissue;'' U.S.Patent No. 5,846,807, entitled ``Media 
Compositions for Three-Dimensional Mammalian Tissue Growth Under 
Microgravity Culture Conditions;'' U.S. Patent No. 5,858,783, entitled 
``Production of Normal Mammalian Organ Culture Using a Medium 
Containing Mem-Alpha, Leibovitz L-15, Glucose Galactose Fructose;'' 
U.S. Patent No. 5,851,816, entitled ``Cultured High-Fidelity Three 
Dimensional Human Urogenital Tract Carcinomas and Process;'' and U.S. 
Patent No. 6,117,674, entitled ``Horizontal Rotating-Wall Vessel 
Propagation in Vitro Human Tissue Models.'' Each of the above U.S. 
Patents is assigned to the United States of America as represented by 
the Administrator of the National Aeronautics and Space Administration. 
Written objections to the prospective grant of a license should be sent 
to the Johnson Space Center.

DATES: Responses to this notice must be received by March 19, 2001.

FOR FURTHER INFORMATION CONTACT: James Cate, Patent Attorney, NASA 
Johnson Space Center, Mail Stop HA, Houston, TX 77058-8452; telephone 
(281) 483-1001.

    Dated: January 9, 2001.
Edward A. Frankle,
General Counsel.
[FR Doc. 01-1125 Filed 1-12-01; 8:45 am]
BILLING CODE 7510-01-U
agreement, Kennedy stated that he was entering his plea freely and

voluntarily without threats or promises of any kind. Although Kennedy testified at the evidentiary hearing that this statement was a lie and he pleaded guilty because he feared for his own safety and the safety of his family, and he testified that his confessions to the police were false, the district court determined that this testimony was not credible. The court noted that Kennedy wrote a statement that was attached to the presentence investigation report in which he admitted to robbing a bar. When questioned about this at the evidentiary hearing, Kennedy acknowledged that the only bar he was charged with robbing was the Alibi Lounge, he did not fear for his safety or the safety of his family when he wrote the statement, and he was not coerced into writing that statement. The district court also noted that although Kennedy was given an opportunity to address the court at sentencing, Kennedy did not assert at the time that he was innocent of the Alibi Lounge robbery and he never indicated to the court that he entered his plea under duress. Kennedy explained at the evidentiary hearing that he did not inform the court of the prior duress or move to withdraw his plea to the Alibi Lounge robbery because he thought the sentencing consequences would be the same. The district court found that Kennedy failed to demonstrate that he was acting under duress when he entered his guilty plea. We conclude that the totality of the circumstances supports the district court's determination that the plea was voluntarily entered, State v. Freese, 116 Nev. 1097, 1104, 13 P.3d 442, 447 (2000), and, therefore, the district court did not abuse its discretion by denying this claim.

Kennedy also claims that the district court erred by denying his claim that his counsel was ineffective for failing to investigate an alibi

SUPREME COURT

OF NEVADA

(0) 1947A 2witness. When reviewing the district court's resolution of an ineffectiveassistance claim, we give deference to the court's factual findings if supported by substantial evidence and not clearly erroneous but review the court's application of the law to those facts de novo. Lader v. Warden, 121 Nev. 682, 686, 120 P.3d 1164, 1166 (2005). The district court found that counsel was not ineffective because the alleged alibi witness testified at the evidentiary hearing that she would not have cooperated with counsel had counsel interviewed her and counsel credibly testified that he was never aware that there was a possible alibi witness. See Strickland v. Washington, 466 U.S. 668. 687-88 (1984);Hill v. Lockhart, 474 U.S. 52, 58- 59 (1985). The record supports the district court's findings, and we
conclude the district court did not err as a matter of law.

Having concluded that Kennedy's claims lack merit, we ORDER the judgment of the district court AFFIRMED.

cc: Hon. Brent T. Adams, District Judge Mary Lou Wilson Attorney General/Carson City Washoe County District Attorney Washoe District Court Clerk

SUPREME COURT

OF NEVADA

(0) 1947A 3
Exhibit (10)(a)

    

    

    

    

    

    

    Consent of Ernst & Young LLP, Independent Registered Public Accounting Firm

    

    

    

    

    We consent to the reference to our firm under the caption “Independent Registered Public Accounting Firm” in Post-Effective Amendment No. 13 to the 1933 Act
      Registration Statement (Form N-4 No. 333-214143) and Amendment No. 741 to the 1940 Act Registration Statement (Form N-4 No. 811-08517), and to the use therein of our reports dated (a) March 13, 2019, with respect to the
      consolidated financial statements of The Lincoln National Life Insurance Company and (b) April 16, 2019, with respect to the financial statements of Lincoln Life Variable Annuity Account N for the registration of interests in a separate account under
      individual flexible payment deferred variable annuity contracts.

    

    

    /s/ Ernst & Young, LLP

    

    

    

    

    

    Philadelphia, Pennsylvania

    December 20, 2019